Logo

Chugai Initiates P-III Clinical Study of Actemra for COVID-19 Pneumonia in Japan

Share this

Chugai Initiates P-III Clinical Study of Actemra for COVID-19 Pneumonia in Japan

Shots:

  • Chugai has filed a clinical trial notification with the PMDA to conduct a P-III clinical study of Actemra (tocilizumab- IV- 80mg/200mg/400mg) to treat hospitalized patients with severe COVID19 pneumonia in Japan
  • The company will start enrolling once the details of the diseases get finalized. Earlier- Roche has initiated P-III COVACTA study assessing Actemra + SOC vs PBO + SOC in hospitalized patients with severe COVID-19 pneumonia across the globe including the US- Canada and EU
  • Actemra is a humanized anti-human IL-6 receptor mAb and has received the US FDA’s approval for RA in 2010 and was launched in Jun’2005 for multiple indications in Japan

Click here ­to­ read full press release/ article | Ref: Roche | Image: Chugai


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions